Core Insights - Alnylam Pharmaceuticals reported quarterly earnings of $2.9 per share, significantly exceeding the Zacks Consensus Estimate of $1.67 per share, and compared to a loss of $0.5 per share a year ago, representing an earnings surprise of +73.65% [1] - The company achieved revenues of $1.25 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 22.25%, and showing a substantial increase from year-ago revenues of $500.92 million [2] - Alnylam shares have increased approximately 104.7% since the beginning of the year, outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, including current consensus earnings expectations for upcoming quarters and any recent changes in these expectations [4] - The current consensus EPS estimate for the coming quarter is $1.86 on revenues of $1.18 billion, and for the current fiscal year, it is $4.44 on revenues of $3.56 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Alnylam belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

Core Insights - Alnylam Pharmaceuticals is experiencing solid improvement in earnings estimates, which may lead to continued stock price momentum [1][2] - Analysts are optimistic about the earnings prospects of Alnylam, driving higher estimates that correlate with stock price movements [2][3] Earnings Estimates - Current-quarter earnings estimate is $1.65 per share, reflecting a year-over-year increase of +430.0% [6] - The Zacks Consensus Estimate for the current quarter has risen by 20.29% over the last 30 days, with two estimates increasing and one decreasing [6] - For the full year, the earnings estimate is $3.81 per share, indicating a significant change of +19,150.0% from the previous year [7] - The consensus estimate for the current year has increased by 8.52% due to two upward revisions and no negative revisions [8] Zacks Rank - Alnylam currently holds a Zacks Rank 2 (Buy), indicating promising estimate revisions and potential for outperformance [9] - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [9] Stock Performance - Alnylam's stock has increased by 6.2% over the past four weeks due to strong estimate revisions [10] - There may still be further upside potential in the stock, suggesting it could be a good addition to investment portfolios [10]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Alnylam Pharmaceuticals (ALNY) - Alnylam Pharmaceuticals currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook based on historical performance metrics [3] Performance Metrics - Over the past week, ALNY shares increased by 0.9%, while the Zacks Medical - Biomedical and Genetics industry declined by 0.34% [5] - In the last quarter, ALNY shares rose by 44.29%, and over the past year, they gained 63.33%, significantly outperforming the S&P 500, which increased by 6.33% and 14.66% respectively [6] - The average 20-day trading volume for ALNY is 1,102,099 shares, indicating a bullish trend when combined with rising stock prices [7] Earnings Outlook - In the past two months, three earnings estimates for ALNY have been revised upwards, while none have been lowered, raising the consensus estimate from $3.35 to $3.98 [9] - For the next fiscal year, two estimates have increased, while one has decreased, reflecting a generally positive earnings outlook [9] Conclusion - Given the strong performance metrics and positive earnings outlook, ALNY is positioned as a promising investment opportunity with a Momentum Score of A [11]

Core Insights - Alnylam Pharmaceuticals (ALNY) is experiencing solid improvement in earnings estimates, which may lead to continued short-term price momentum [1][2] - The rising trend in estimate revisions reflects growing analyst optimism regarding the company's earnings prospects, which is expected to positively impact its stock price [2][3] Current-Quarter Estimate Revisions - The company is projected to earn $0.50 per share for the current quarter, indicating a year-over-year increase of +200.0% [6] - The Zacks Consensus Estimate for Alnylam has risen by 62.96% over the last 30 days, with four estimates increasing and no negative revisions [6] Current-Year Estimate Revisions - For the full year, Alnylam is expected to earn $1.61 per share, representing a year-over-year change of +8,150.0% [7] - The trend for current-year estimate revisions is positive, with six estimates moving higher and no negative revisions [7] Zacks Rank - Alnylam currently holds a Zacks Rank 2 (Buy), indicating promising estimate revisions that can guide investment decisions [8] - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [8] Bottom Line - Investors have shown confidence in Alnylam due to solid estimate revisions, reflected in a 21.1% stock gain over the past four weeks, suggesting potential for further growth [9]

Core Viewpoint - The market anticipates Alnylam Pharmaceuticals (ALNY) to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Financial Expectations - Alnylam is expected to report a quarterly loss of $0.03 per share, reflecting a year-over-year change of -105.4% [3]. - Revenues are projected to be $671.11 million, which is a 1.7% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 62.96% higher in the last 30 days, indicating a reassessment by analysts [4]. - A positive Earnings ESP of +831.25% suggests that analysts have recently become more optimistic about Alnylam's earnings prospects [12]. Earnings Surprise History - In the last reported quarter, Alnylam was expected to post a loss of $0.56 per share but actually reported a loss of -$0.01, resulting in a surprise of +98.21% [13]. - Over the past four quarters, Alnylam has beaten consensus EPS estimates three times [14]. Industry Comparison - Incyte (INCY), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post earnings of $1.4 per share for the same quarter, indicating a year-over-year change of +176.9% [18]. - Incyte's revenues are expected to reach $1.15 billion, up 10.3% from the previous year [18].

Core Viewpoint - Alnylam Pharmaceuticals (ALNY) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Stock Performance - The Zacks rating system focuses on a company's changing earnings picture, with the Zacks Consensus Estimate tracking EPS estimates from sell-side analysts [2]. - A strong correlation exists between changes in earnings estimates and near-term stock price movements, with institutional investors using these estimates to assess fair value [5]. Recent Developments for Alnylam - Alnylam's earnings estimates have seen a notable increase, with the Zacks Consensus Estimate for the fiscal year ending December 2025 rising by 52.6% [9]. - The upgrade to Zacks Rank 2 places Alnylam in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [11]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [8]. - The system maintains a balanced distribution of "buy" and "sell" ratings across over 4,000 stocks, ensuring that only the top 5% receive a "Strong Buy" rating [10].

Company Overview - Alnylam Pharmaceuticals (ALNY) is expected to report a year-over-year decline in earnings with a quarterly loss of $0.56 per share, reflecting a -250% change, while revenues are anticipated to be $587.72 million, an increase of 18.9% from the previous year [3][12]. Earnings Expectations - The consensus EPS estimate has been revised 5.17% lower in the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][10]. - The Earnings ESP for Alnylam is -12.28%, suggesting a lower Most Accurate Estimate compared to the Zacks Consensus Estimate, which complicates the prediction of an earnings beat [11][10]. Historical Performance - Alnylam has beaten consensus EPS estimates three times in the last four quarters, with a notable surprise of +128.57% in the last reported quarter [12][13]. Industry Context - In the broader Zacks Medical - Biomedical and Genetics industry, GSK is expected to report earnings of $1.08 per share, reflecting a -0.9% year-over-year change, with revenues projected at $9.54 billion, up 2.2% from the previous year [17]. - GSK's consensus EPS estimate has also been revised 1.9% lower, resulting in an Earnings ESP of -0.93%, making it difficult to predict an earnings beat [18].